TNM staging
TNM staging, which stands for Tumor, Node, and Metastasis, is a standardized system used to assess the extent and severity of solid malignant tumors, including those in the breast, colorectal, kidney, lung, and prostate, among others. This staging is crucial as it serves as the most significant predictor of survival and informs treatment options and clinical trial eligibility for patients. The system evaluates three main components: the size and extent of the primary tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastases (M). Each of these factors is rated numerically, allowing healthcare professionals to communicate effectively about cancer cases.
Developed by the American Joint Committee on Cancer and the Union for International Cancer Control, TNM staging has evolved over time and continues to adapt with advancements in medical understanding. It plays a vital role not only in treatment planning but also in epidemiological studies by helping to standardize data collection across different cancer types. Staging is performed through various diagnostic methods, including imaging studies and biopsy, and is essential in guiding patient care following diagnosis. Understanding TNM staging can empower patients and caregivers by providing clarity on the nature of the disease and its management.
On this Page
Subject Terms
TNM staging
ALSO KNOWN AS: Tumor/nodes/metastases staging
DEFINITION: TNM (an abbreviation for tumor, node, and metastasis) staging is a system used to describe the extent and severity of solid malignant tumors and how much they have spread.
Cancers diagnosed or treated: Solid tumors such as breast, colorectal, kidney, larynx, lung, and prostate cancers and melanoma
Why performed:Staging of cancer is necessary because the stage at diagnosis is the most powerful predictor of survival. Doctors use staging information to help plan a patient’s treatment, estimate a patient’s prognosis, select changes in treatment, and identify appropriate clinical trials for patients.
TNM staging provides a common language with which oncologists and all other members of the healthcare team can communicate when discussing cancer patients, as well as evaluate and compare the results of clinical trials. Staging data, when collected over time, can be valuable to epidemiologists for analysis of similar types of cancer or use in special studies.
Patient preparation: Tissue samples are taken from tumors; patient preparation depends on the type of tumor and its location. Often, samples are taken as part of the surgical process to remove the tumor.
Steps of the procedure: Staging is based on an understanding of how cancer develops. A tumor is formed at the primary site as cancer cells grow and divide in an uncontrolled fashion. As a tumor grows, its cells can invade neighboring tissues or leave the tumor to migrate through the bloodstream or lymph system to new sites in the body, a process called metastasis.
Staging systems for cancer have evolved over time and continue to be upgraded as cancer becomes better understood. The American Joint Committee on Cancer, established in 1988 to address the inadequacies of the traditional method of staging cancer using I-IV, created the TNM system for staging solid tumors throughout the body. The Union for International Cancer Control also maintains the TNM system outside the United States. Most types of solid tumors have TNM designations, although some do not (for example, cancers of the brain, blood, and spinal cord). In the TNM system, each factor is evaluated separately and given a number. For instance, a T1N1M0 cancer means the patient has a T1 tumor, N1 lymph node involvement, and no metastases.
The precise definitions of T, N, and M are specific to each type of cancer, but general definitions of each element are tumor, node, and metastasis. Tumor (T) describes the size and extent of the primary tumor and carries a number of 0 to 4, with 0 being a small tumor that is entirely contained at the local site and 4 being a large primary tumor that has probably involved other organs. Node (N) describes regional lymph node metastasis and can be ranked from 0 to 3, with 0 being no lymph node involvement and 3 being extensive involvement. Metastasis (M) describes the presence or absence of distant metastases; it is 1 if distant metastases are present and 0 if not. For example, breast cancer T3N2M1 describes a large tumor that has spread outside the breast to nearby and other parts of the body, whereas prostate cancer T2N0M0 describes a tumor located only in the prostate that has not spread to the lymph nodes or any other part of the body.
The category X is used in each element where no assessment of that characteristic was made. For example, NX indicates that the status of lymph nodes was not assessed. It is important not to confuse this category with N0, which indicates that no lymph node involvement was found by the diagnostic tools used.
The types of tests that are used for staging depend on the type of cancer but can include physical examination; imaging studies such as X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), or positron emission tomography (PET) scans; laboratory values such as tests for liver function or tumor markers; pathology reports; and surgical reports. The TNM system has evolved as advances have been made in the diagnosis and treatment of different types of cancer. For instance, endoscopic ultrasound imaging of esophageal and rectal tumors has improved the accuracy of the clinical T, N, and M classifications. Advances in treatment have necessitated more detail in some T4 categories.
Clinical TNM staging and pathological TNM staging are distinct evaluations. Clinical staging is based on all available information obtained before pathology results are available. It may include information obtained by physical examination, radiologic examination, and endoscopy, for example. Pathologic staging includes information gained by microscopic examination of the primary tumor and regional lymph nodes. These two categories of staging are denoted by a small c or p before the stage, such as cT2N2M0 or pT3N4M1. It is also possible to stage a case at recurrence after a disease-free interval, at which time an r precedes the TNM designation.
When advances are made that affect the staging of a particular type of cancer, the TNM staging system changes to reflect this as well. New versions of the TNM protocols are released for the specific cancer when this occurs. For example, in 2021, a ninth version of TNM staging was released for cervical cancer to reflect new knowledge regarding human papillomavirus-associated and human papillomavirus-independent carcinomas. New versions of the TNM stages for specific cancers are published as new science becomes available.
After the procedure: Aftercare depends on the type of biopsy taken and whether the patient was placed under anesthesia. For most types of biopsy for which a patient is not already hospitalized, patients will arrange transportation to and from the healthcare facility and will have a family member or friend’s supervision afterward. Often, a postsurgical hospital stay is required.
Risks: The risks to patients are related to the type of sample taken and the disease involved.
Results: Staging is an important aspect of understanding a patient’s cancer. It guides treatment decisions and provides insight into the patient’s prognosis.
Bibliography
Bernick, P. E., and W. D. Wong. “Staging: What Makes Sense? Can the Pathologist Help?” Surgical Oncology Clinics of North America, vol. 9, 2000, pp. 703-720.
“Cancer Staging.” National Cancer Institute, 14 Oct. 2022, www.cancer.gov/about-cancer/diagnosis-staging/staging. Accessed 16 June 2024.
“Cancer Staging Systems.” American College of Surgeons, www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/cancer-staging-systems. Accessed 16 June 2024.
Greene, F. L., et al., eds. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer, 2011.
Kehoe, J., and V. P. Khatri. “Staging and Prognosis of Colon Cancer.” Surgical Oncology Clinics of North America, vol. 15, 2006, pp. 129-146.
MacManus, Daniel. “TNM Staging System - Radiology Reference Article.” Radiopaedia, 7 June 2024, radiopaedia.org/articles/tnm-staging-system-2?lang=us. Accessed 16 June 2024.
Olawaiye, Alexander B., et al. "The New (Version 9) American Joint Committee on Cancer Tumor, Node, Metastasis Staging for Cervical Cancer." CA: A Cancer Journal for Clinicians, vol. 71, no. 4, 2021, pp. 287-298, doi.org/10.3322/caac.21663. Accessed 16 June 2024.
Sobin, L. H. “TNM: Evolution and Relation to Other Prognostic Factors.” Seminars in Surgical Oncology, vol. 21, 2003, pp. 3-7.